by April Breyer Menon | Mar 19, 2019
While the biosimilar market in the U.S. has gotten off to a relatively slow start compared to Europe, where biosimilars have been available since 2006, it has recently gained momentum and will continue to grow in the coming years as more “blockbuster” biologics lose...
by April Breyer Menon | Feb 27, 2019
In an article for Patent Lawyer Magazine, Ha Kung Wong and April Breyer Menon of Venable discuss how high barriers to biosimilar market entry may make government development and manufacturing challenging under the Affordable Drug Manufacturing Act. Download PDF Ha...
by April Breyer Menon | Dec 31, 2018
The Center for Biosimilars asked experts from across stakeholder groups—and from the United States and abroad—what they felt were the most notable moments in biosimilars during 2018, and what they hope the new year holds for this developing industry. Venable partner...
by April Breyer Menon | Nov 12, 2018
Download PDF Download...
by April Breyer Menon | Nov 6, 2018
Ha Kung Wong addresses ongoing biosimilar cases that stakeholders are watching closely as part of a video series for the Center for Biosimilars. Transcript: Are there some ongoing cases that biosimilar stakeholders are watching closely at the moment?...
by April Breyer Menon | Nov 1, 2018
Venable’s highly-rated Intellectual Property practice adds strength. New York and Washington (November 1, 2018) – Venable LLP, an American Lawyer Global 100 firm, today announced that Fitzpatrick, Cella, Harper & Scinto, a leading intellectual property firm, has...